Fewer than 5,000 people prescribed anticholesterol drug inclisiran in primary care as of July 2023
Exclusive: Despite NHS England’s target for 300,000 patients to be using inclisiran by October 2024, 4,549 people had been prescribed it in primary care between October 2021 and July 2023.
Inclisiran uses RNA interference to boost the liver’s ability to remove harmful cholesterol from the blood
Shutterstock.com
Fewer than 5,000 people in England have been prescribed the novel anticholesterol drug inclisiran (Leqvio; Novartis) in primary care since its approval by the National Institute for Health and Care Excellence (NICE) in October 2021, NHS data show.
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
